A phase II, randomized, double-blind, placebo-controlled trial of Trans-sodium crocetinate in hemorrhagic and ischemic stroke patients
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Transcrocetinate sodium (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms PHAST-TSC
- 01 Feb 2018 According to a Diffusion Pharmaceuticals media release, this study will be conducted in co-operation with the University of California Los Angeles (UCLA) and the University of Virginia (UVA).
- 29 Jan 2018 New trial record
- 24 Jan 2018 According to a Diffusion Pharmaceuticals media release, the design and rationale for the trial will be presented at the International Stroke Conference 2018.